Anti-E-selectin is ineffective in the treatment of psoriasis: a randomized trial

M. Bhushan; T.O. Bleiker; A. E. Ballsdon; Michael H. Allen; Mark Sopwith; M K Robinson; Cosmos C. Clarke; Richard Weller; R.A.C. GRAHAM-BROWN; M. Keefe; Juliet N. Barker; Christopher Em Griffiths

doi:10.1046/j.1365-2133.2002.04743.x

Back

Anti-E-selectin is ineffective in the treatment of psoriasis: a randomized trial

Article 2002 en

Abstract

1 min read

This clinicopathological study shows that anti-E-selectin (CDP850), although a well-tolerated, logical and safe therapy, does not appear to possess a therapeutic role in the treatment of chronic plaque psoriasis.

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Article2005

Controversies in Experimental Dermatology

Christopher Em Griffiths

Article2004

T-Cell-Targeted Biologicals for Psoriasis

Christopher Em Griffiths

Article2003

An International, Randomized, Double-blind, Placebo-Controlled Phase 3 Trial of Intramuscular Alefacept in Patients With Chronic Plaque Psoriasis

Mark Lebwohl, Enno Christophers, Richard G. Langley, Jean Paul Ortonne, Janet L. Roberts, Christopher Em Griffiths

Article2016

Investigation of selective JAK1 inhibitor GSK2586184 for the treatment of psoriasis in a randomized placebo-controlled phase IIa study

Valerie J. Ludbrook, Kirsty Hicks, Kate Hanrott, Jatin Patel, Michael Binks, Melody Wyres, Joanna Watson, Phebe Wilson, Monica Simeoni, Lorrie Schifano, Kristian Reich, Christopher Em Griffiths

Article2001

Psoriasis 2000: the state-of-the-art today ... and tomorrow

Christopher Em Griffiths